Making Disease-Risk Visible Through Genomic Screening
Dr. Mike Murray is board certified in Internal Medicine and Medical Genetics and he joined Geisinger Health System as the director of clinical genomics in 2013 after serving on the faculty at Harvard Medical School and as the clinical chief of genetics at Brigham and Women’s Hospital in Boston for nine years.
At Geisinger he has led the design and implementation of the GenomeFIRST return of results program for the over 150,000 patient participants who undergo genomic sequencing as part of the MyCode Community Health Initiative. This project builds on the collaboration between Geisinger and Regeneron Pharmaceuticals, but is funded outside of that research collaboration through internal Geisinger support, external grants, and generous donations. The GenomeFIRST return of results program expects to deliver important risk information based on genetic sequence back to between 3-4% of MyCode participants in its initial phase. These risks primarily fall into the categories of either risk for cancer or cardiovascular disease. Geisinger is the first institution in the world to build the necessary infrastructure at the scale needed to deliver this kind of genomic results to this many patients and their providers, and to then assist the patients in getting their at-risk family members tested too. This program can now serve as one source for pilot data as programs for Genomic-Based Population Screening in Adults are designed.